Global Information
회사소개 | 문의 | 위시리스트

세계의 자궁내막증 시장

Endometriosis

리서치사 Global Industry Analysts, Inc.
발행일 2019년 05월 상품 코드 236863
페이지 정보 영문 181 Pages
가격
US $ 5,600 ₩ 6,833,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 16,800 ₩ 20,499,000 PDF by E-mail (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 자궁내막증 시장 Endometriosis
발행일 : 2019년 05월 페이지 정보 : 영문 181 Pages

세계의 자궁내막증(Endometriosis) 시장에 대해 조사했으며, 시장 개요와 성장 동향, 제품 개요, 시장에 참여하는 기업 개요 등의 정보를 전해드립니다.

제1장 서론, 조사 방법, 제품 정의

제2장 주요 요약

  • 업계 개요
  • 자궁내막증과 치료법
    • 서론
    • 여성의 자궁내막증 발증
    • 원인과 징조
    • 자궁내막증의 종류
    • 주요 진단 기술
    • 환자 카운셀링
    • 재발
    • 자궁내막증과 암
    • 자궁내막증 연구 센터
  • 자궁내막증 치료
    • 자궁내막증과 이용 가능한 치료법
    • 자궁내막증 치료 메커니즘
  • 비스테로이드 항염증제(NSAID)
  • 비호르몬 치료
  • 수술
  • 보완 치료
  • 임상시험/제품 혁신과 인가
  • 제품 개요
  • 최근 업계 활동
  • 주요 기업
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Debiopharm Group
    • Evotec AG
    • Kissei Pharmaceutical Co., Ltd.
    • Neurocrine Biosciences, Inc.
    • ObsEva SA
    • Pfizer, Inc.
    • Repros Therapeutics, Inc.
    • Roivant Sciences GmbH
    • Takeda Pharmaceutical Company Limited
    • ValiRx plc
  • 세계 시장 전망

제3장 시장

  • 미국
  • 캐나다
  • 일본
  • 유럽
  • 아시아태평양
KSM 18.03.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 38 companies including many key and niche players such as -

AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Debiopharm Group
Evotec AG

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Endometriosis: An Introductory Prelude
  • Endometriosis Facts in a Nutshell
  • Poor Efficacy & Safety Profiles of Existing Drugs Lead to Unmet Medical Needs
  • Key Endometriosis Drugs on the Market
    • Table 1: Leading Endometriosis Drugs on the Market (2017E): Percentage Breakdown of Revenues for Depo-Provera, Lupron, Visanne, Zoladex and Others (includes corresponding Graph/Chart)
  • The Pipeline Review
    • Key Endometriosis Drugs in the Pipeline: 2017
  • Steady Growth Expected Over the Next Few Years
  • Emerging Treatment for Endometriosis & Endometrial Cancer
  • Global Awareness Campaigns and Efforts
  • Uptrend in Healthcare Expenditure Creates Substantial Opportunities
    • Table 2: Healthcare Spending as % of GDP by Geographic Region (2016) (includes corresponding Graph/Chart)
    • Table 3: Per Capita Healthcare Spending (in $) in Select Developed Countries for the Year 2016 (includes corresponding Graph/Chart)
  • Developed Regions Remain Primary Revenue Contributors
    • Table 4: Developed Regions Account for over 90% Share of World Endometriosis Drugs Market: Percentage Breakdown of Value Sales for Developed Regions and Developing Regions (2017E & 2022P) (includes corresponding Graph/Chart)
  • Developing Regions Exhibit Immense Growth Potential
  • Stable Economic Scenario to Augment Market Prospects
    • Table 5: World Real GDP Growth Rates in % (2016-2018P): Breakdown by Country/Region (includes corresponding Graph/Chart)

2. ENDOMETRIOSIS & ITS TREATMENT - AN OVERVIEW

  • Introduction
  • Occurrence of Endometriosis in Women
  • Causes and Symptoms
  • Causes
    • Estrogen Theory
    • Mullerianosis Theory
    • Retrograde Menstruation Theory
    • Coelomic Metaplasia Theory
    • Hereditary Factors
    • Environmental Factors
      • Dioxin Behavior in the Body
    • Birth Defects
    • Other Causes
  • Symptoms of Endometriosis
    • Reasons for Pain due to Endometriosis
    • Endometriosis and Infertility
  • Kinds of Endometriosis
  • Reproductive Area Endometriosis
  • Uterosacral/Presacral Nerve Endometriosis
  • Cul-de-Sac ("Pouch of Douglas") Endometriosis
  • Gastrointestinal Endometriosis
  • Pleural (lung/chest cavity/diaphragmatic) Endometriosis
  • Urinary Tract (kidneys, ureters, bladder and urethra) Endometriosis
  • Skin Endometriosis
  • Sciatic Endometriosis
  • Stages of Endometriosis
  • Diagnosis of Endometriosis
  • Major Diagnostic Techniques
  • Pelvic Exam
  • Laparoscopy
  • Other Diagnostic Procedures
  • A New Non-invasive Test for the Diagnosis of Endometriosis
  • Endometriosis Markers
  • Counseling of patients
  • Recurrence of Endometriosis
  • Endometriosis & Infertility
  • Miscarriage
  • Endometriosis & Thyroid Autoimmunity
  • Relationship between Endometriosis and Autoimmune Disease
  • Endometriosis & Cancer
  • Associations & Research Centers
  • The Endometriosis Association
  • Endometriosis Research Center

3. TREATMENT OF ENDOMETRIOSIS

  • Endometriosis & Available Treatment Options
  • Endometriosis Treatment Mechanisms: In a Nutshell

I. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

  • II. Hormonal Therapy
  • Gonadotropin Releasing Hormone (Gnrh) Agonists
    • Select Major GnRH-Agonists for Endometriosis Treatment
    • Lupron, Zoladex and Synarel - The Major Drugs
    • AbbVie's Lupron(r) (Leuprorelin)
    • AstraZeneca's Zoladex(r) (Goserelin)
    • Pfizer's Synarel (Nafarelin Acetate)
  • Add-back Medication
  • Progestogens
    • Select Major Progestins for Endometriosis Treatment
    • Combined Oral Contraceptive Pill
    • Danazol and Other Suppressive Steroids
  • Chinese Herbs - More Effective than Danazol or Gestrinone
  • Aromatase Inhibitors

III. Non-hormonal Therapy

  • Anti-Angiogenic Agents
  • Selective COX-2 Inhibitors
  • TNF-Alpha Inhibitors

IV. Surgical Techniques

V. Complementary Therapies

  • Long-term Approach to Pain
  • Lifestyle Modifications
  • Chinese Herbs
  • Treatment for Endometriosis-related Infertility
  • Hormonal Treatment
    • Minimal to Mild Endometriosis
    • Moderate-Severe Endometriosis
  • Surgical Treatment
    • Minimal-Mild Endometriosis
    • Moderate-Severe Endometriosis
  • Treatment for Ovarian Endometriosis
  • Surgical Vs. Medicinal Interventions
    • Medicinal Interventions
      • Advantages
      • Disadvantages
    • Surgery
      • Advantages
      • Disadvantages
  • In-vitro Fertilization
  • Other Treatment

4. SELECT CLINICAL TRIALS/PRODUCT INNOVATIONS & APPROVALS

  • AbbVie and Neurocrine Bag US FDA Priority Review Clearance for Elagolix
  • AbbVie Announces Results from Replicate Phase 3 Extension Studies for Elagolix
  • Bayer Commences Enrolling Patients for Phase III Program to Study Vilaprisan's Efficacy in Treating Symptomatic UF
  • ObsEva to Commence Phase 2b EDELWEISS Clinical Trial of OBE2109
  • Repros Keeps Proellex(r) Development Program on Partial Clinical Hold of FDA
  • Aeterna Zentaris Halts Development of Zoptrex(tm)
  • Evotec and Bayer's Endometriosis Alliance Portfolio Advances into Phase I Clinical Development
  • ObsEva Commences Phase 3 Clinical Program to Evaluate OBE2109 to Treat UF
  • Myovant Achieves Positive Phase 3 Study Results for Relugolix in Treating UF
  • Myovant Commences Phase 3 Program of Relugolix for Treating Endometriosis-Associated Pain
  • Repros Therapeutics' Achieves Positive Results from Proellex Phase II Study
  • ValiRx Bags European Patent for VAL201
  • Virexxa Receives FDA Clearance to Proceed to Phase II
  • OBE2109 by ObsEva Receives IND Clearance
  • Galena Biopharma Presents Phase 1/2a Data on Endometrial Cancer Immunotherapies
  • AbbVie and Neurocrine Report Positive Phase 3 Trial Data of Elagolix
  • ValiRx Plc to Begin Endometriosis Clinical Research with its VAL201
  • Aurobindo Pharma Receives FDA Approval to Market Tablets for Endometriosis Treatment
  • Lumenis to Introduce UltraPulse DUO CO2 laser system and FemTouch Solution
  • Bayer Launches Phase II Trials of vilaprisan for Endometriosis Treatment
  • Nippon Shinyaku Conducts Phase I Evaluation of NS 580 for Endometriosis Therapy
  • Teleflex to Showcase its Surgical Solutions for Endometriosis
  • ValiRx Plc Receives Patent Grant for VAL201

5. RECENT INDUSTRY ACTIVITY

  • AstraZeneca Bags Commercial Rights to Zoladex
  • Astellas Pharma to Acquire Ogeda
  • Roivant Establishes New Global Headquarters in Basel
  • Takeda and Roivant Partner to Form Myovant
  • Evotec-Bayer Collaboration Reaches Important Clinical Milestones for Endometriosis Therapy
  • ObsEva and Kissei Pharmaceutical Enter Into Collaboration Agreement for KLH-2109

6. FOCUS ON SELECT GLOBAL PLAYERS

  • AbbVie Inc. (USA)
  • Astellas Pharma Inc. (Japan)
  • AstraZeneca Plc (UK)
  • Bayer AG (Germany)
  • Debiopharm Group (Switzerland)
  • Evotec AG (Germany)
  • Kissei Pharmaceutical Co., Ltd. (Japan)
  • Neurocrine Biosciences, Inc. (USA)
  • ObsEva SA (Switzerland)
  • Pfizer, Inc. (USA)
  • Repros Therapeutics, Inc. (USA)
  • Roivant Sciences GmbH (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • ValiRx plc (UK)

7. GLOBAL MARKET PERSPECTIVE

    • Table 6: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 7: World Historic Review for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 8: World 14-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Largest Market for Endometriosis Drugs
    • Endometriosis Associations Increase Awareness
    • Newer Diagnostic Methods Yet to Expand Across the Country
    • Key Endometriosis Drugs on the Market
    • Product Launches/Clinical Trials
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 9: The US Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 10: The US Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Product Launch
    • Key Players
  • B. Market Analytics
    • Table 11: Canadian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 12: Canadian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Clinical Trial
    • Key Players
  • B. Market Analytics
    • Table 13: Japanese Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 14: Japanese Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

  • Market Analysis
    • Table 15: European Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 16: European Historic Review for Endometriosis Drugs by Geographic Region/ Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 17: European 14-Year Perspective for Endometriosis Drugs by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Programmes to Maintain Endometriosis Database
  • B. Market Analytics
    • Table 18: French Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 19: French Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Clinical Trials
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 20: German Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 21: German Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 22: Italian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 23: Italian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Product Launches/Clinical Trials
    • Key Players
  • B. Market Analytics
    • Table 24: The UK Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 25: The UK Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 26: Spanish Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 27: Spanish Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • A. Market Analysis
    • Product Launches/Clinical Trials
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 28: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 29: Rest of Europe Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • The Rapidly Growing Market
    • Endometriosis Therapeutics in Australia
  • B. Market Analytics
    • Table 30: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 31: Asia-Pacific Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Product Launch
  • B. Market Analytics
    • Table 32: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 33: Rest of World Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Back to Top
전화 문의
F A Q